AIM's Rabies Vaccine Nears Market Entry, Signals Strong Valuation Rebound
April 08, 2025 | 11:23
AIM Vaccine Co., Ltd., announced on April 7, 2025 that the company's research and development of the serum-free iterative rabies vaccine has received an "Acceptance Notice" from the National Medical Products Administration for market registration.
Mobile Version